NRXP Latest Press Releases

-- October 30, 2026 --

NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date Globe Newswire 7:00 AM

-- October 29, 2026 --

NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine Globe Newswire 4:00 PM

-- October 19, 2026 --

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine Globe Newswire 8:30 AM

-- October 15, 2026 --

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine Globe Newswire 8:27 AM

-- September 30, 2026 --

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression Globe Newswire 7:00 AM

-- September 15, 2026 --

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine Globe Newswire 3:11 PM

-- September 14, 2026 --

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) Globe Newswire 7:00 AM

-- September 11, 2026 --

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System Globe Newswire 7:00 AM

-- September 8, 2026 --

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 17, 2026 --

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET Globe Newswire 7:00 AM

-- August 7, 2026 --

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans Globe Newswire 4:01 PM

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval Globe Newswire 7:00 AM

-- June 25, 2026 --

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute Globe Newswire 4:01 PM

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System Globe Newswire 7:00 AM

-- June 24, 2026 --

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition Business Wire 1:18 PM

-- June 23, 2026 --

ZETA SURGICAL Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics PRNewswire 11:06 AM

-- June 22, 2026 --

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression Globe Newswire 7:00 AM

-- June 5, 2026 --

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. Globe Newswire 8:50 AM

-- June 4, 2026 --

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option Globe Newswire 5:12 PM

-- June 3, 2026 --

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock Globe Newswire 8:18 AM

-- June 2, 2026 --

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes